As Professor in Directed Evolution and Antibody Technology, Johan Rockberg heads a research group of ten at KTH Royal Institute of Technology, Stockholm. His research team has a strong method development focus, directed at both discovery and bioprocess development of next generation biologics, including gene therapy and immunomodulating bi-specific antibodies. To this end, directed evolution and systems biology are tools used for improvement of both compound and producer cell lines. A particular research interest is human cell homeostasis and secretional machinery during stress such as upon viral propagation or during bioreactor cultivation. He is the director of AAVNova, for the development of next generation bioproduction platforms for virus-based gene therapy. Since 2019, Prof. Rockberg is an elected member of the Swedish Young Academy. He has been holding industry positions as Director Biosynergy at Alligator Bioscience AB, Lund Sweden, as CSO of Atlas Therapeutics AB, Stockholm Sweden and is a co-founder of Abclon Inc, Seoul South-Korea, all focused on cancer immunotherapy.